NNMX $0.0002 on 02 Jan 2026 Market Hours: Oversold bounce, model shows upside
NNMX stock trades at USD 0.0002 on the PNK exchange during market hours on 02 Jan 2026, marking an ultra-low float situation with market cap USD 9,799.00 and one share traded at the open. This price places Nanomix Corporation in an extreme oversold state versus its 200-day average USD 0.00016 and 50-day average USD 0.00020. We assess why the current setup reads as an oversold bounce candidate, connect fundamentals and liquidity constraints to price action, and show model-driven upside scenarios for active traders and cautious investors.
Price and volume snapshot
NNMX (Nanomix Corporation) is priced at USD 0.0002 with day low and high both USD 0.0002 and previous close USD 0.0002. Volume is 1 share versus average volume 25 shares, highlighting extremely thin liquidity. Market capitalisation is USD 9,799.00 on PNK in the United States and shares outstanding are 48,996,800, which magnifies volatility when even a handful of shares trade.
Why this looks like an oversold bounce
Price sits near its year low USD 0.0001 and the 50-day and 200-day averages are USD 0.00020 and USD 0.0001565 respectively, indicating price compression around micro-penny levels. Low trading activity (avgVolume 25) plus a tiny market cap creates rapid, headline-driven moves; an oversold bounce can occur when short-term buyers test liquidity at these levels.
Fundamentals and financial metrics
Trailing EPS is negative at -0.31 and the reported PE is non-standard at approximately -0.00065, reflecting losses and a negligible share price. Key ratios show price-to-sales 0.63 and enterprise value to sales approximately 737.80, and operating cash flow per share is -0.15042, underlining operational cash burn and weak liquidity (current ratio 0.02).
Technical view and Meyka grade
On technical reads, standard indicators are largely flat or unavailable due to minimal price dispersion and near-zero historical volume, which makes RSI and MACD unreliable for NNMX. Meyka AI rates NNMX with a score out of 100: 69.29 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. This grade is informational only and not investment advice.
Risks and potential catalysts
Primary risks include extreme illiquidity, continued cash burn, low revenue per share (USD 0.00038) and corporate execution risk in the healthcare / medical devices space. Potential catalysts that could trigger a bounce are clinical progress or corporate updates about product trials, a meaningful liquidity event, or improved market attention; absent those, price can remain rangebound or decline.
Trading strategy: oversold bounce approach
For traders targeting an oversold bounce, use small position sizing, strict stop-loss rules and confirm any move with volume greater than the 50-day average. Scenario-based price targets for planning: downside support USD 0.0001, conservative target USD 0.0010, base recovery USD 0.0100, optimistic model target USD 0.45344 — size positions accordingly given the risk profile.
Final Thoughts
Key takeaways: NNMX stock trades at USD 0.0002 on PNK (United States) with a market cap of USD 9,799.00 and near-zero liquidity, which creates a classic oversold bounce environment for nimble traders. Fundamentals show negative EPS of -0.31 and constrained cash flow, so any bounce requires either a structural change in liquidity or material company news. Meyka AI’s forecast model projects USD 0.45344 as a yearly model-based projection, implying an upside of about 226,619.04% from the current USD 0.0002 price; forecasts are model-based projections and not guarantees. Given the mix of extreme volatility, small float, and weak fundamentals, our scenario planning recommends small, risk-managed sizing and clear stop-losses for traders seeking an oversold bounce while longer-term investors should wait for clearer operating improvements.
FAQs
NNMX may offer short-term bounce potential due to extreme oversold conditions, but severe liquidity and negative EPS (-0.31) make it high risk. Use small position sizes and strict stops; this is not a recommendation.
Main risks are ultra-low liquidity, negative operating cash flow per share (-0.15042), tiny market cap USD 9,799.00, and reliance on clinical or corporate updates to move price materially.
Meyka AI rates NNMX 69.29 out of 100 (Grade B, Suggestion: HOLD). The grade weighs benchmark and sector comparisons, financial metrics and forecasts; it is informational only and not financial advice.
Meyka AI’s forecast model projects USD 0.45344 for the year. Compared with current USD 0.0002 price this implies a very large modelled upside; forecasts are model outputs and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
